Commonwealth Equity Services LLC boosted its holdings in TESARO Inc (NASDAQ:TSRO) by 93.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,675 shares of the biopharmaceutical company’s stock after acquiring an additional 6,139 shares during the quarter. Commonwealth Equity Services LLC’s holdings in TESARO were worth $724,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in TSRO. TimesSquare Capital Management LLC raised its position in TESARO by 226.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 856,600 shares of the biopharmaceutical company’s stock worth $70,986,000 after acquiring an additional 593,924 shares in the last quarter. BB Biotech AG raised its position in TESARO by 55.8% in the first quarter. BB Biotech AG now owns 1,629,743 shares of the biopharmaceutical company’s stock worth $93,124,000 after acquiring an additional 583,550 shares in the last quarter. Renaissance Technologies LLC raised its position in TESARO by 482.1% in the fourth quarter. Renaissance Technologies LLC now owns 357,400 shares of the biopharmaceutical company’s stock worth $29,618,000 after acquiring an additional 296,000 shares in the last quarter. Frontier Capital Management Co. LLC purchased a new position in TESARO in the first quarter worth $13,843,000. Finally, BlackRock Inc. raised its position in TESARO by 5.6% in the fourth quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock worth $337,039,000 after acquiring an additional 213,920 shares in the last quarter.
Shares of TESARO opened at $44.47 on Friday, Marketbeat reports. The company has a debt-to-equity ratio of 3.74, a current ratio of 4.02 and a quick ratio of 3.56. The firm has a market capitalization of $2.39 billion, a PE ratio of -4.85 and a beta of 1.23. TESARO Inc has a fifty-two week low of $38.40 and a fifty-two week high of $143.45.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of ($2.56) by ($0.42). The company had revenue of $49.74 million for the quarter, compared to analyst estimates of $56.34 million. TESARO had a negative net margin of 193.42% and a negative return on equity of 177.92%. The firm’s revenue was up 1520.2% on a year-over-year basis. During the same period in the previous year, the business earned ($2.55) EPS. sell-side analysts anticipate that TESARO Inc will post -10.08 earnings per share for the current fiscal year.
TSRO has been the subject of several research analyst reports. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a research report on Friday, March 2nd. BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 6th. HC Wainwright restated a “buy” rating and issued a $108.00 price target on shares of TESARO in a research report on Tuesday, March 27th. Lake Street Capital set a $120.00 price target on TESARO and gave the company a “buy” rating in a research report on Sunday, April 22nd. Finally, Robert W. Baird restated a “hold” rating on shares of TESARO in a research report on Tuesday, April 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $111.24.
In related news, Director Lawrence M. Alleva sold 7,142 shares of the stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $43.11, for a total transaction of $307,891.62. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 33.70% of the stock is owned by company insiders.
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.